Sources
Sources & Further Reading
Every source cited in this hub, with direct links to primary documents. All links go to the original source — no paywalled summaries where the primary document is freely available.
Primary sources
Directly cited in the hub. Linked to the original document wherever possible.
Darling Ingredients press release announcing the Rousselot US patent. The primary source for the Case Studies section of this hub.
FDA database of excipients (including gelatin grades) already approved in marketed drug products at specific exposure levels. Key reference for formulation IP strategy.
The FDA rule establishing BSE/TSE sourcing requirements for bovine-derived materials including gelatin used in food, cosmetics, and dietary supplements.
The foundational US law creating the modern generic drug approval pathway and patent term restoration (PTE) for brand-name drugs. Full text via Congress.gov.
The law establishing the 12-year reference product exclusivity period for biologics and the biosimilar approval pathway. Relevant to the calculator's biologic product type.
The law establishing 7-year orphan drug exclusivity for drugs treating rare diseases. Relevant to the calculator's orphan drug product type.
The statutory basis for Patent Term Extension (PTE). Covers eligibility, calculation method, the 5-year cap, and the 14-year post-approval protection cap.
The US Pharmacopeia-National Formulary monograph for gelatin, specifying identity, purity, and quality standards for pharmaceutical-grade gelatin. Access requires USP subscription.
The PDG coordinates harmonization of the USP-NF, Ph. Eur., and JP gelatin monographs. The PDG work program page tracks harmonization status.
FDA Select Committee on GRAS Substances (SCOGS) reports on gelatin, documenting the scientific basis for GRAS status. Searchable via the FDA GRAS database.
Further reading
Not directly cited but useful background for the topics covered in this hub.
Congressional Research Service analysis of the Hatch-Waxman Act's effects on generic drug competition and patent term restoration. Useful background on the policy context.
FDA guidance on the two generic/modified drug approval pathways. Relevant to understanding how excipient IP interacts with the approval process.
Darling Ingredients' Rousselot brand page, providing context on the company's position in the pharmaceutical gelatin market.
Link rot is real. If a link above is broken, the source can usually be found via the Wayback Machine or by searching the issuing organization directly. Report broken links to [email protected].